<DOC>
	<DOC>NCT00210444</DOC>
	<brief_summary>To evaluate the effect on healing rates of two different prognostic factors in patients treated with Dysport® for anal fissure: duration of fissure and dose of study drug</brief_summary>
	<brief_title>Efficacy Study of Dysport® in the Treatment of Anal Fissure.</brief_title>
	<detailed_description />
	<mesh_term>Fissure in Ano</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients having idiopathic anal fissure in the posterior anal midline Patients having anal fissure present for less than 6 months Patients having symptoms (pain) present for a minimum of 2 weeks and not responding after 2 weeks of standard therapy (diet, laxatives, sitzbathes) Patients having anal fistulas or anal fissure of various causes such as Crohn disease, Behcet infectious ulceration, anal suppuration, subfissural infiltration, abscesses, acute haemorrhoidal attacks or inflammatory bowel disease Patients having idiopathic anal fissure in the anterior anal midline Patients having lateral or multiple fissures Patients having anal or perianal cancer Patients who underwent previous anal surgery or have cicatricial alterations or postsurgical cicatricial lesions Patients receiving drugs affecting neuromuscular transmission Patients who have received topical anaesthetic within 3 days of injection Patients receiving local treatment by myorelaxing agent Patients receiving prohibited analgesics Patients having bleeding disturbances or currently using coumarin derivates Patients having myasthenia or any genetic muscle disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>